Product Name: AHA1
Product Number: AB-NN191-4
| Size: | 25 µl | Price: | 89.00 | |
| $US |
Target Full Name: Activator of 90 kDa heat shock protein ATPase homologue 1
Target Alias: Activator of heat shock 90kDa protein ATPase homologue 1; AHA 1; AHA1; AHSA 1; AHSA1; AHSA1_HUMAN; C14orf3; HSPC322; p38 antibody
Product Type Specific: AHA1 pan-specific antibody
Antibody Code: NN191-4
Antibody Target Type: Pan-specific
Protein UniProt: O95433
Protein SigNET: O95433
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Ig Isotype Clone: N/A
Antibody Immunogen Source: Mouse Aha1
Target Alias: Activator of heat shock 90kDa protein ATPase homologue 1; AHA 1; AHA1; AHSA 1; AHSA1; AHSA1_HUMAN; C14orf3; HSPC322; p38 antibody
Product Type Specific: AHA1 pan-specific antibody
Antibody Code: NN191-4
Antibody Target Type: Pan-specific
Protein UniProt: O95433
Protein SigNET: O95433
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Ig Isotype Clone: N/A
Antibody Immunogen Source: Mouse Aha1
Production Method: Protein A purified
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH7.4, 50% glycerol, 0.09% sodium azide
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Immunohistochemistry | ICC/Immunofluorescence | Immunoprecipitation | ELISA
Antibody Dilution Recommended: WB (1:1000); optimal dilutions for assays should be determined by the user.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH7.4, 50% glycerol, 0.09% sodium azide
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Immunohistochemistry | ICC/Immunofluorescence | Immunoprecipitation | ELISA
Antibody Dilution Recommended: WB (1:1000); optimal dilutions for assays should be determined by the user.
Antibody Potency: High potency. Detects a ~38 kDa protein in cell and tissue lysates by Western blotting. Can migrate as a 45 kDa protein on SDS-PAGE gels based on immunoreactivity with recombinant Aha1.
Antibody Species Reactivity: Human | Mouse | Rat
Antibody Positive Control: 1 µl/ml of SPC-183 was sufficient for detection of Aha1 in 10 µg of mixed human cell lysate by colorimetric immunoblot analysis using Goat anti-mouse IgG:HRP as the secondary antibody.
Antibody Specificity: Medium-high
Related Product 1: AHA1 pan-specific antibody (Cat. No.: AB-NN190-1)
Related Product 2: AHA1 pan-specific antibody (Cat. No.: AB-NN190-2)
Related Product 3: AHA1 pan-specific antibody (Cat. No.: AB-NN191-3)
Antibody Species Reactivity: Human | Mouse | Rat
Antibody Positive Control: 1 µl/ml of SPC-183 was sufficient for detection of Aha1 in 10 µg of mixed human cell lysate by colorimetric immunoblot analysis using Goat anti-mouse IgG:HRP as the secondary antibody.
Antibody Specificity: Medium-high
Related Product 1: AHA1 pan-specific antibody (Cat. No.: AB-NN190-1)
Related Product 2: AHA1 pan-specific antibody (Cat. No.: AB-NN190-2)
Related Product 3: AHA1 pan-specific antibody (Cat. No.: AB-NN191-3)
Scientific Background: Aha1 is a member of the HSP90 cochaperone family, and is thought to stimulate HSP90 ATPase activity by competing with p23 and other co-chaperones for HSP90 binding (1, 2). It may affect a step in the endoplasmic reticulum to Golgi trafficking. Aha1 also interacts with HSPCA/HSP90 and with the cytoplasmic tail of the vesicular stomatistis virus glycoproteins (VSV G) (3). Aha1 is expressed in numerous tissues, including the brain, heart, skeletal muscle, and kidney, and at low levels, the liver and placenta. Aha1 might be a potential therapeutic strategy to increase sensitivity to HSP inhibitors (4).
References
[1] Hainzl O., Lapina M.C., Buchner J., Richter K. (2009) J Biol Chem. Epub.
[2] Harst A., Lin H., Obermann W.M. (2005) Biochem J. 387 (pt.3): 789-796.
[3] Lotz G.P., Brychzy A., Heinz S., Obermann W.M. (2008) J Cell Sci. 121(pt.5): 717-723.
[4] Holmes J.L., Sharp S.Y., Hobbs S., Workman P. (2008) Cancer Res. 68(4): 1188-1197.
[1] Hainzl O., Lapina M.C., Buchner J., Richter K. (2009) J Biol Chem. Epub.
[2] Harst A., Lin H., Obermann W.M. (2005) Biochem J. 387 (pt.3): 789-796.
[3] Lotz G.P., Brychzy A., Heinz S., Obermann W.M. (2008) J Cell Sci. 121(pt.5): 717-723.
[4] Holmes J.L., Sharp S.Y., Hobbs S., Workman P. (2008) Cancer Res. 68(4): 1188-1197.
© Kinexus Bioinformatics Corporation 2017